Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

被引：51
|
作者：
Kang, Jin [1 ,2 ,3 ]
Chen, Hua-Jun [2 ,3 ]
Wang, Zheng [4 ]
Liu, Jing [5 ]
Li, Bing [5 ]
Zhang, Tengfei [5 ]
Yang, Zhenfan [4 ]
Wu, Yi-Long [2 ,3 ,6 ]
Yang, Jin-Ji [1 ,2 ,3 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Cardiovasc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[4] AstraZeneca, Asia Innovat Med, Shanghai, Peoples R China
[5] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
ACQUIRED-RESISTANCE; CANCER;
D O I：
10.1016/j.jtho.2017.10.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E49 / E53
页数：5
相关论文
共 50 条
  • [1] The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
    Jori, Balazs
    Voessing, Christine
    Pirngruber, Judith
    Willing, Eva Maria
    Arndt, Kathrin
    Falk, Markus
    Tiemann, Markus
    Heukamp, Lukas C.
    Hoffknecht, Petra
    CURRENT ONCOLOGY, 2023, 30 (10) : 8805 - 8814
  • [2] Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
    Gautschi, Oliver
    Menon, Roopika
    Bertrand, Miriam
    Murer, Christian
    Diebold, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : E13 - E15
  • [3] Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib
    Schmid, Sabine
    Stewart, Erin L.
    Martins-Filho, Sebastiao N.
    Cabanero, Michael
    Wang, Ao
    Bao, Hua
    Wu, Xue
    Patel, Deval
    Chen, Zhuo
    Law, Jennifer H.
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Leighl, Natasha
    Tsao, Ming-Sound
    Pugh, Trevor
    Bratman, Scott, V
    Sacher, Adrian
    Liu, Geoffrey
    CLINICAL LUNG CANCER, 2020, 21 (05) : E488 - E492
  • [4] MET second-site mutations in EGFR-mutant, MET-amplified non-small cell lung cancer after resistance to combinatorial targeted therapy.
    Cheng, Jia-Tao
    Yang, Jinji
    Wu, Yilong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
  • [6] Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung
    Dietrich, Martin Frederik
    Yan, Shirley Xiao
    Schiller, Joan Hoff
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) : E23 - E25
  • [7] Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
    Takamori, Shinkichi
    Seto, Takashi
    Yamaguchi, Masafumi
    Kinoshita, Fumihiko
    Fujishita, Takatoshi
    Ito, Kensaku
    Toyozawa, Ryo
    Shoji, Fumihiro
    Okamoto, Tatsuro
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.
    Kang, Jin
    Li, Xiang-Meng
    Cheng, Jia-Tao
    Chen, Huajun
    Zhang, Xuchao
    Tu, Hai-Yan
    Zhou, Qing
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
    Corassa, Marcelo
    Abreu, Rodrigo Fonseca
    Cordeiro de Lima, Vladmir Claudio
    Torrezan, Giovana Tardim
    Cavalher, Felicia Peterson
    Silva, Tullio Novaes
    de Oliveira, Thiago Bueno
    Freitas, Helano Carioca
    Carraro, Dirce Maria
    Costa, Felipe D'Almeida
    JCO PRECISION ONCOLOGY, 2022, 6
  • [10] Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells
    Yamaoka, Toshimitsu
    Ohmori, Tohru
    Ohba, Motoi
    Murata, Yasunori
    Kishino, Yasunari
    Kusumoto, Sojiro
    Ishida, Hiroo
    Ohnishi, Tsukasa
    Sasakii, Yasutsuna
    CANCER RESEARCH, 2016, 76
12345